Lantern Pharma Inc. (NasdaqCM: LTRN)
Health Care · Biotechnology · US
$0.67
-17.76% today · -83.8% 1Y
Lantern Pharma Inc. (NasdaqCM: LTRN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $8.54M and employs 16 people.
Over the last twelve months the share price has lost 83.8%, trading between 0.63 and 4.34.
Tweenvest scores Lantern Pharma Inc. across four factors: quality 29/100, value 24/100. Its strongest factor is quality.
LTRN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.54M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.63
- Dividend yield
- —
- Beta (5Y)
- 2.32
- 52-week high
- $4.34
- 52-week low
- $0.63
- Avg volume (3M)
- —
- Shares outstanding
- 12.78M
- Employees
- 16
- Next earnings
- —
About Lantern Pharma Inc.
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
- ISIN
- US51654W1018
- Founded
- 2013
- Listed since
- Jun 11, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| 1nKemia IUCT Group, S.A.BME: IKM | $8.80M | €— | — |
| Nanologica AB (publ)OM: NICA | $8.66M | Skr0.26 | -5.78% |
| Brainstorm Cell Therapeutics Inc.OTCPK: BCLI | $8.60M | $0.78 | -17.94% |
| Chemomab Therapeutics Ltd.NasdaqCM: CMMB | $8.55M | $1.18 | +0.85% |
| Adaptimmune Therapeutics plcOTCPK: ADAP.Y | $8.48M | $0.03 | +6.67% |
| Eusol Biotech Co.,Ltd.UNQ: 6652 | $8.45M | NT$— | — |
| Active Biotech AB (publ)OM: ACTI | $8.34M | Skr3.14 | -10.94% |
| MetaVia Inc.NasdaqCM: MTVA | $8.30M | $1.26 | -10.64% |
Figures last refreshed Oct 18, 2026.